Skip to Content

Rule

New Animal Drugs; Change of Sponsor's Drug Labeler Code

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of drug labeler code for Med-Pharmex, Inc.

DATES:

This rule is effective March 16, 2006.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Charles Eastin, Center for Veterinary Medicine (HFV-210), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9077, e-mail: charles.eastin@fda.hhs.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

FDA has found that the animal drug regulations do not reflect the correct drug labeler code for Med-Pharmex, Inc. Accordingly, the agency is amending the regulations in 21 CFR 510.600, 520.1044a, 520.1195, 520.1484, 520.1485, 520.2220a, 520.2345d, 522.900, 524.1044b, 524.1044f, 524.1044g, 524.1193, 524.1443, 524.1580b, 524.1580e, 524.1600a, 524.2481, and 529.1044b to correct this error. In addition, 21 CFR 524.1044b, 524.1044f, 524.1443, and 524.2481 are being revised to reflect a current format.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

, 522, 524, and 529

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Amend § 510.600 in the table in paragraph (c)(1) in the entry for “Med-Pharmex, Inc.” by removing “051259” and by adding in its place “054925”; and in the table in paragraph (c)(2) by removing the entry for “051259” and by

End Amendment Part
Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c) * * *

(2) * * *

Drug labeler codeFirm name and address
*    *    *    *    *
054925Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767-1861
*    *    *    *    *
Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. In paragraph (b) of § 520.1044a, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

5. In paragraph (b)(2) of § 520.1195, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

6. In paragraph (b)(1) of § 520.1484, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

7. In paragraph (b) of § 520.1485, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

8. In paragraphs (a)(1) and (a)(2) of § 520.2220a, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

9. In paragraphs (b)(5), (d)(1)(iii), and (d)(2)(iii) of § 520.2345d, remove “051259” and add in its place “054925”.

End Amendment Part Start Part

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

10. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

11. In paragraph (b)(1) of § 522.900, remove “051259” and add in its place “054925”.

End Amendment Part Start Part

PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

12. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

13. Revise § 524.1044b to read as follows:

End Amendment Part
Gentamicin sulfate, betamethasone valerate otic solution.

(a) Specifications. Each milliliter of solution contains gentamicin sulfate equivalent to 3 milligrams (mg) gentamicin base and betamethasone valerate equivalent to 1 mg betamethasone alcohol.

(b) Sponsors. See Nos. 000061 and 054925 in § 510.600(c) of this chapter.

(c) Conditions of use—(1) Amounts and indications for use—(i) For the treatment of acute and chronic otitis externa caused by bacteria sensitive to gentamicin in dogs, instill three to eight drops of solution into the ear canal twice daily for 7 to 14 days.

(ii) For the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin in dogs and cats, apply a sufficient amount of the drug to cover the treatment area twice daily for 7 to 14 days.

(2) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Start Amendment Part

14. Revise § 524.1044f to read as follows:

End Amendment Part
Gentamicin sulfate, betamethasone valerate topical spray.

(a) Specifications. Each milliliter of spray contains gentamicin sulfate equivalent to 0.57 milligram (mg) gentamicin base and betamethasone valerate equivalent to 0.284 mg betamethasone.

(b) Sponsors. See Nos. 000061 and 054925 in § 510.600(c) of this chapter.

(c) Conditions of use in dogs—(1) Amount. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer two spray actuations two to four times daily for 7 days.

(2) Indications for use. For the treatment of infected superficial lesions caused by bacteria sensitive to gentamicin.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[Amended]
Start Amendment Part

15. In paragraph (b)(2) of § 524.1044g, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

16. In paragraph (b)(2) of § 524.1193, remove “051259, 051311” and add in its place “051311, 054925”.

End Amendment Part Start Amendment Part

17. Revise § 524.1443 to read as follows:

End Amendment Part
Miconazole.

(a) Specifications—(1) Each gram of cream contains miconazole nitrate equivalent to 20 milligrams miconazole base.

(2) Each gram of lotion or spray contains miconazole nitrate equivalent to 1 percent miconazole base.

(b) Sponsors. See § 510.600(c) of this chapter for use as in paragraph (c) of this section:

(1) No. 000061 for use of cream, lotion, and spray;

(2) Nos. 054925 and 058829 for use of lotion and spray.

(c) Conditions of use in dogs and cats—(1) Amount. Apply once daily by rubbing into or spraying a light covering on the infected site and the immediate surrounding vicinity. Continue treatment for 2 to 4 weeks until infection is completely eradicated as determined by appropriate laboratory examination.

(2) Indications for use. For topical treatment of infections caused by Microsporum canis, Microsporum gypseum, and Trichophyton mentagrophytes.

(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[Amended]
Start Amendment Part

18. In paragraph (b)(1) of § 524.1580b, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

19. In paragraph (b) of § 524.1580e, remove “051259” and add in its place “054925”.

End Amendment Part
[Amended]
Start Amendment Part

20. In paragraph (b) of § 524.1600a, remove both occurrences of “051259, and 053501” and add in their places “053501, and 054925”.

End Amendment Part Start Amendment Part

21. Revise § 524.2481 to read as follows:

End Amendment Part
Triamcinolone cream.

(a) Specifications. The vanishing cream contains 0.1 percent triamcinolone acetonide.

(b) Sponsor. See Nos. 053501 and 054925 in § 510.600(c) of this chapter.

Start Printed Page 13543

(c) Conditions of use in dogs—(1) Amount. Rub into affected areas two to four times daily for 4 to 10 days.

(2) Indications for use. As an anti-inflammatory, antipruritic, and antiallergic agent for topical treatment of allergic dermatitis and summer eczema.

(3) Limitations. Federal law restricts this drug to use only by or on the order of a licensed veterinarian.

Start Part

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

22. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

23. In paragraph (b) of § 529.1044b, remove “

End Amendment Part Start Signature

Dated: March 7, 2006.

Steven D. Vaughn,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 06-2554 Filed 3-15-06; 8:45 am]

BILLING CODE 4160-01-S